ADC Therapeutics SA ADCT Stock
ADC Therapeutics SA Price Chart
ADC Therapeutics SA ADCT Financial and Trading Overview
ADC Therapeutics SA stock price | 1.35 USD |
Previous Close | 2.29 USD |
Open | 2.27 USD |
Bid | 2.32 USD x 900 |
Ask | 2.61 USD x 1400 |
Day's Range | 2.27 - 2.36 USD |
52 Week Range | 1.85 - 10.88 USD |
Volume | 157.23K USD |
Avg. Volume | 511.53K USD |
Market Cap | 186.28M USD |
Beta (5Y Monthly) | 1.082883 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.62 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10.67 USD |
ADCT Valuation Measures
Enterprise Value | 220.45M USD |
Trailing P/E | N/A |
Forward P/E | -0.9871795 |
PEG Ratio (5 yr expected) | 0.27 |
Price/Sales (ttm) | 1.0212835 |
Price/Book (mrq) | 4.9570813 |
Enterprise Value/Revenue | 1.209 |
Enterprise Value/EBITDA | -1.651 |
Trading Information
ADC Therapeutics SA Stock Price History
Beta (5Y Monthly) | 1.082883 |
52-Week Change | -63.62% |
S&P500 52-Week Change | 20.43% |
52 Week High | 10.88 USD |
52 Week Low | 1.85 USD |
50-Day Moving Average | 2.28 USD |
200-Day Moving Average | 3.64 USD |
ADCT Share Statistics
Avg. Volume (3 month) | 511.53K USD |
Avg. Daily Volume (10-Days) | 259.83K USD |
Shares Outstanding | 80.64M |
Float | 50.5M |
Short Ratio | 14.57 |
% Held by Insiders | 32.60% |
% Held by Institutions | 64.31% |
Shares Short | 6.07M |
Short % of Float | 13.55% |
Short % of Shares Outstanding | 7.53% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -108.86% |
Operating Margin (ttm) | -73.79% |
Gross Margin | 9.32% |
EBITDA Margin | -73.20% |
Management Effectiveness
Return on Assets (ttm) | -16.032% |
Return on Equity (ttm) | -198.21% |
Income Statement
Revenue (ttm) | 182.4M USD |
Revenue Per Share (ttm) | 2.31 USD |
Quarterly Revenue Growth (yoy) | -59.19% |
Gross Profit (ttm) | 35.1M USD |
EBITDA | -133529000 USD |
Net Income Avi to Common (ttm) | -198564992 USD |
Diluted EPS (ttm) | -2.27 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 310.55M USD |
Total Cash Per Share (mrq) | 3.84 USD |
Total Debt (mrq) | 345.96M USD |
Total Debt/Equity (mrq) | 918.02 USD |
Current Ratio (mrq) | 4.686 |
Book Value Per Share (mrq) | 0.466 |
Cash Flow Statement
Operating Cash Flow (ttm) | -117683000 USD |
Levered Free Cash Flow (ttm) | -70353128 USD |
Profile of ADC Therapeutics SA
Country | United States |
State | N/A |
City | Epalinges |
Address | Biopole |
ZIP | 1066 |
Phone | 41 21 653 02 00 |
Website | https://www.adctherapeutics.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 317 |
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7, a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL). The company is also developing camidanlumab tesirine, an ADC composed of a monoclonal antibody that binds to CD25 conjugated to a PBDdimer toxin, as well as in Phase II clinical trial in relapsed or refractory hodgkin lymphoma. In addition, it develops ADCT-602, which is in Phase I/II clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 that are in Phase Ia clinical trial for treatment of various solid tumors and hematological malignancies; and ADCT-212, a second-generation PBD-based ADC targeting prostate-specific membrane antigen (PSMA), including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Q&A For ADC Therapeutics SA Stock
What is a current ADCT stock price?
ADC Therapeutics SA ADCT stock price today per share is 1.35 USD.
How to purchase ADC Therapeutics SA stock?
You can buy ADCT shares on the NYSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ADC Therapeutics SA?
The stock symbol or ticker of ADC Therapeutics SA is ADCT.
Which industry does the ADC Therapeutics SA company belong to?
The ADC Therapeutics SA industry is Biotechnology.
How many shares does ADC Therapeutics SA have in circulation?
The max supply of ADC Therapeutics SA shares is 99.08M.
What is ADC Therapeutics SA Price to Earnings Ratio (PE Ratio)?
ADC Therapeutics SA PE Ratio is now.
What was ADC Therapeutics SA earnings per share over the trailing 12 months (TTM)?
ADC Therapeutics SA EPS is -1.62 USD over the trailing 12 months.
Which sector does the ADC Therapeutics SA company belong to?
The ADC Therapeutics SA sector is Healthcare.
ADC Therapeutics SA ADCT included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NYSE COMPOSITE (DJ) NYA | 19398.28 USD — |
+0.01
|
— — | 19204.15 USD — | 19463.54 USD — | — - | — — |
- {{ link.label }} {{link}}